PDCD1 and neoplasm: With the tumor environment related to the outcome of immune checkpoint inhibitor treatments40,41, our study found that low-risk patients demonstrated higher levels of CTLA-4, PD-1, and PD-L1, suggesting that immunotherapies targeting these entities could be more beneficial for such patients.